ezetimibe has been researched along with avapro in 6 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (avapro) | Trials (avapro) | Recent Studies (post-2010) (avapro) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 1,369 | 385 | 495 |
| Protein | Taxonomy | ezetimibe (IC50) | avapro (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 7.3067 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0099 | |
| Type-2 angiotensin II receptor | Homo sapiens (human) | 0.003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, S; Chen, Y; Fu, L; Zhang, L | 1 |
| Dong, Z; Ekins, S; Polli, JE | 1 |
| Blanchet, M; Labonté, P; Sureau, C | 1 |
2 review(s) available for ezetimibe and avapro
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential.
Topics: Carcinoma, Hepatocellular; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Hepatocytes; Humans; Interferons; Liver Neoplasms; Nucleotides; Organic Anion Transporters, Sodium-Dependent; Symporters; Virus Internalization | 2022 |
4 other study(ies) available for ezetimibe and avapro
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP).
Topics: Azetidines; Bayes Theorem; Biphenyl Compounds; Computational Biology; Ezetimibe; Humans; Irbesartan; Organic Anion Transporters, Sodium-Dependent; Structure-Activity Relationship; Symporters; Tetrazoles; United States; United States Food and Drug Administration | 2013 |
Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.
Topics: Antiviral Agents; Azetidines; Biphenyl Compounds; Cell Line; Ezetimibe; Hepatitis B virus; Hepatitis Delta Virus; Hepatocytes; Humans; Irbesartan; Organic Anion Transporters, Sodium-Dependent; Receptors, Virus; Ritonavir; Symporters; Tetrazoles; Virus Internalization | 2014 |